Exciting news from Ionis Pharmaceuticals! Potentially faster approval for HTTRx!

Ionis Pharmaceuticals.jpg

Ionis Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to IONIS-HTTRx for the treatment of people with Huntington's disease (HD). This PRIME designation means this potentially disease-modifying drug for people with Huntington's disease to regulatory approval faster. This is exciting news! Read the full press release.